Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I'm hoping for news soon. Been accumulating.
Time to stock up.
I don't know about that, but it is clear that pharmas around the world are interested and it is providing non dilutive capital to advance their other pipeline.
bremelanotide a failure?? Can you explain?
I look at V as a non dilutive way to finance their other phase 2 drugs, which have a fairly big market potential.
Clear. Perfect.
Understood. Thank again!
Thank you. So low absorption or even no absorption is a good thing?
Can someone explain what is meant by the statement below? What if they had observed it?
Although absorption of Brilacidin was not observed from analysis of plasma concentrations, this was not unexpected and may indeed be a desirable attribute for a drug that acts by virtue of its local effect on inflamed mucosal surfaces within the lower GI tract.
I'm not sure I agree. UC is a big market. The further they move the drug by themselves then the more profitable the partnership.
Still doesn't make sense to me why he left or was fired. Can't imagine he left on his own with being close to next steps. Cost cutting move while we wait on B OM offer, failure to achieve deal, ....
My guess is at JP conference is that they will also meet investor that may help them go it alone on B OM
BooDog, I've been thinking about that possibility and how that would translate into shareholder value. It doesn't add up for me unless he is looking to sell the company. Maybe I'm missing something.
Any thoughts on how the company will perform in 2020?
To me, what's more frustrating is the darts at a target approach. I can understand failing at P but to misunderstand the B OM market is difficult to swallow.
What's your point?
Has it been communicated yet the results of the FDA review of the 2 reagents?
What would be an acceptable B OM deal? I'm thinking partner pays all development and commercial similar to B UP. But, IPIX also receives $30M in upfront and development milestones along with teens royalties.
Not just "ongoing", but they have said notable progress and multiple companies. That's where I cannot reconcile the shareholder alert. Notable should not have been used if the offer wasn't in the ballpark. To me notable is...pass the hard stuff...not just room for negotiation.
Thank you LR. Actually I was referring to the Nov 25 PR.
Seems at this point we push UC oral as far as we can. Hope AS makes progress on B UP. Still not sure that we have received an update on that progress. B OM could be a while if still searching for an acceptable offer.
I missed something Epicare. Can you tell me where did he mentioned this?
Makes sense. Was hoping internal path meant something different. I guess debt finance is not an option. Maybe sell the ABSSSI portion.
Or as Frrol alludes to...the pharmas are just not that into it so the offers are weaker than desired. LW should help understand the market better, which might include Leo adjusting his opinion. Sounds more like we will go it alone through some type of internal path....whatever that means.
Wierd day. One thing is certain. LW was hired for BOM.
What examples do you have of mgt screwing shareholders?
Makes sense. But, part of me thinks they are in final negotiations with OM and have gotten this far without LW. Seems LW site mentions in examples a time frame of around 5 months for bigger deals assuming they got in at ground level. It's why I think perhaps they are looking ahead. I lean towards OM, but then again...maybe it's both. I also think combining with another company that has capital is also and option.
But, maybe LW was brought in the the IBD market? Maybe not OM.
Seems we could sell the rights to B ABSSSI for a small price to a specialty antibiotic company.
Perhaps LW was brought in for oral B UC as it takes 3-5 months for that size of deal, in my opinion. Maybe they are further along in B OM negotiations it appears.
As if last week, Dr B said...
"Negotiations with potential pharmaceutical partners interested in licensing our Brilacidin for OM asset continue, with the Company remaining diligent as it works toward executing the next step in the drug candidate’s development."
But, I'm sure he was lying or half truth telling or trying to get SP up or something. Surely he's not accurate.
I still believe there are advanced negotiations ongoing for OM. Could be that either they are attempting to close the deal at $ acceptable to both parties or are still keeping the doors open for a higher bidder. Either way, the additional shares provide financial flexibility.
And all development paid. I'm sure ipix will greatly benefit from the development.
Maybe this will help.
"we worked with respective manufacturers of these reagents to satisfy the FDA's questions and subsequently submitted a complete response to the FDA in late October."
You doubt? I generally agree with your conservatism and skepticism of companies and posters but on this I differ. LW focuses on closing deals, which is why they are selective. From LW website...
Locust Walk has a robust record of success in closing high-value transactions for multiple clients
Per LW...“We are very selective in deciding which companies to work with,” said Chris Ehrlich, Managing Director and Global Head of Biopharma at Locust Walk.
Fair response Loanranger. Just to add that LW is very selective in deciding with whom to work and that IP is already in advanced negotiations. Further to the point, PR stated to determine the market Potential and best path forward.
Or they were brought in to close a transaction where notable progress has been made in advanced negotiations.
I suspect we'll get some type of update on Monday or Tuesday. It's been a month since engaging Locust Walk to likely close a deal for B OM.
Lemoncat, can you clarify? Are you thinking another company or investor will pick up the company assets because the company is not likely to find a partner anytime soon? Not sure I follow your thought evolution. Thanks.